Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2011

View Archived Issues

Theophylline improves motor function after stroke

Vitae and Boehringer Ingelheim claim new 11-beta-HSD1 inhibitors

New protein glutamine gamma-glutaminyltransferase 2 inhibitors presented

Verona Pharma provides update on clinical development programs

Sylentis gains approval in Spain to conduct trials of RNAi therapy SYL-1001

Mologen to investigate DNA immunomodulator MGN-1703 in lung cancer

Interim first-in-human data suggest MK-1496 is active against solid tumors

First-in-human phase 0/Ia SM-101 study in healthy volunteers completed

Abagovomab does not prolong survival of patients with ovarian cancer in MIMOSA trial

Liraglutide added to insulin shows promise in treating type 1 diabetes

Merck KGaA prepares novel PI3K inhibitors

Mellitech researchers disclose new insulin secretagogues

GSK presents new serine/threonine-protein kinase B-raf inhibitors

SPX-106 with D-tagatose significantly reduces cholesterol and triglycerides in mice

Grifols completes acquisition of Talecris Biotherapeutics

Evotec and Active Biotech form medicinal chemistry collaboration

GE Healthcare and ImaginAb to develop PET imaging agents based on antibody fragments

NovaDel Pharma files IND with FDA for sildenafil oral spray

AIM Therapeutics begins first-in-human phase I trial of AIM-102

Ferrer files MAA with EMA for tesamorelin

Plexxikon provides update on vemurafenib development program

Adolor completes enrollment in phase II ADL-5945 program

Seaside Therapeutics begins pivotal phase III STX-209 trial in fragile X syndrome

NICE recommends Ozurdex to treat for macular edema due to retinal vein occlusion

Laureate Biopharmaceutical to manufacture Patrys' lead anticancer product, PAT-LM1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.